Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro

References

• Baselga J, Arteaga C L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology 2005; 23: 2445–2459
   PubMed Web of Science ®Google Scholar
• Baselga J, Trigo J M, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2005; 23: 5568–5577
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Zips D, Eicheler W, Dorfler A, Ahrens J, Petersen C, Bruchner K, Hilberg F. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. International Journal of Radiation Biology 2003; 79: 547–559
   PubMed Web of Science ®Google Scholar
• Cordes N. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Research 2004; 64: 5683–5692
   PubMed Web of Science ®Google Scholar
• Cordes N, Seidler J, Durzok R, Geinitz H, Brakebusch C. beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury. Oncogene 2006; 25: 1378–1390
   PubMed Web of Science ®Google Scholar
• Cordes N, van Beuningen D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. British Journal of Cancer 2003; 88: 1470–1479
   PubMed Web of Science ®Google Scholar
• Dittrich C, Greim G, Borner M, Weigang-Kohler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. European Journal of Cancer 2002; 38: 1072–1080
   PubMed Web of Science ®Google Scholar
• Duxbury M S, Ito H, Benoit E, Waseem T, Ashley S W, Whang E E. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clinical Cancer Research 2005; 11: 3433–3438
   PubMed Web of Science ®Google Scholar
• Eke I, Sandfort V, Mischkus A, Baumann M, Cordes N. Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. Radiotherapy and Oncology 2006; 80: 178–184
   PubMed Web of Science ®Google Scholar
• Fehrmann A, Dorr W. Effect of EGFR-inhibition on the radiation response of oral mucosa: Experimental studies in mouse tongue epithelium. International Journal of Radiation Biology 2005; 81: 437–443
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R P, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of Clinical Oncology 2003; 21: 2237–2246
   PubMed Web of Science ®Google Scholar
• Hannigan G E, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino M G, Radeva G, Filmus J, Bell J C, Dedhar S. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996; 379: 91–96
   PubMed Web of Science ®Google Scholar
• Hannigan G, Troussard A A, Dedhar S. Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nature Reviews Cancer 2005; 5: 51–63
   PubMed Web of Science ®Google Scholar
• Held K D. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 1997; 2: 265–282
   PubMed Web of Science ®Google Scholar
• Hendry J H, Potten C S. Intestinal cell radiosensitivity: A comparison for cell death assayed by apoptosis or by a loss of clonogenicity. International Journal of Radiation Biology 1982; 42: 621–628
   Web of Science ®Google Scholar
• Hess F, Estrugo D, Fischer A, Belka C, Cordes N. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 2007; 26: 1372–1384
   PubMed Web of Science ®Google Scholar
• Hynes N E, Lane H A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Reviews Cancer 2005; 5: 341–354
   PubMed Web of Science ®Google Scholar
• Hynes R O. Integrins: Bidirectional, allosteric signaling machines. Cell 2002; 110: 673–687
   PubMed Web of Science ®Google Scholar
• Iliakis G, Wang H, Perrault A R, Boecker W, Rosidi B, Windhofer F, Wu W, Guan J, Terzoudi G, Pantelias G. Mechanisms of DNA double strand break repair and chromosome aberration formation. Cytogenetic and Genome Research 2004; 104: 14–20
   PubMed Web of Science ®Google Scholar
• Kasten-Pisula U, Tastan H, Dikomey E. Huge differences in cellular radiosensitivity due to only very small variations in double-strand break repair capacity. International Journal of Radiation Biology 2005; 81: 409–419
   PubMed Web of Science ®Google Scholar
• Khanna K K, Jackson S P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nature Genetics 2001; 27: 247–254
   PubMed Web of Science ®Google Scholar
• Koul D, Shen R, Bergh S, Lu Y, de Groot J F, Liu T J, Mills G B, Yung W K. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Molecular Cancer Therapeutics 2005; 4: 1681–1688
   PubMed Web of Science ®Google Scholar
• Kris M G, Natale R B, Herbst R S, Lynch T J, Jr., Prager D, Belani C P, Schiller J H, Kelly K, Spiridonidis H, Sandler A, Albain K S, Cella D, Wolf M K, Averbuch S D, Ochs J J, Kay A C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. Journal of the American Medical Association 2003; 290: 2149–2158
   PubMed Web of Science ®Google Scholar
• Liu J, Costello P C, Pham N A, Pintillie M, Jabali M, Sanghera J, Tsao M S, Johnston M R. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. Journal of Thoracic Oncology 2006; 1: 771–779
   PubMed Web of Science ®Google Scholar
• Moro L, Venturino M, Bozzo C, Silengo L, Altruda F, Beguinot L, Tarone G, Defilippi P. Integrins induce activation of EGF receptor: Role in MAP kinase induction and adhesion-dependent cell survival. EMBO Journal 1998; 17: 6622–6632
   PubMed Web of Science ®Google Scholar
• Nuijen B, Bouma M, Henrar R E, Brauns U, Bette P, Bult A, Beijnen J H. In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS. International Journal of Pharmaceutics 2000; 194: 261–267
   PubMed Web of Science ®Google Scholar
• Richter M, Zhang H. Receptor-targeted cancer therapy. DNA and Cell Biology 2005; 24: 271–282
   PubMed Web of Science ®Google Scholar
• Rogers S J, Harrington K J, Rhys-Evans P, P O C, Eccles S A. Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer and Metastasis Reviews 2005; 24: 47–69
   PubMed Web of Science ®Google Scholar
• Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. Proceedings of the National Academy of Sciences USA 2003; 100: 5057–5062
   PubMed Web of Science ®Google Scholar
• Sakai T, Li S, Docheva D, Grashoff C, Sakai K, Kostka G, Braun A, Pfeifer A, Yurchenco P D, Fassler R. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation. Genes & Development 2003; 17: 926–940
   PubMed Web of Science ®Google Scholar
• Solca F F, Baum A, Langkopf E, Dahmann G, Heider K H, Himmelsbach F, van Meel J C. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. Journal of Pharmacology and Experimental Therapy 2004; 311: 502–509
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 2004; 306: 1506–1507
   PubMed Web of Science ®Google Scholar
• Toulany M, Dittmann K, Baumann M, Rodemann H P. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiotherapy and Oncology 2005; 74: 117–129
   PubMed Web of Science ®Google Scholar
• Wang B, Matsuoka S, Carpenter P B, Elledge S J. 53BP1, a mediator of the DNA damage checkpoint. Science 2002; 298: 1435–1438
   PubMed Web of Science ®Google Scholar
• Wu C. PINCH, N(i)ck and the ILK: Network wiring at cell-matrix adhesions. Trends in Cell Biology 2005; 15: 460–466
   PubMed Web of Science ®Google Scholar
• Younes M N, Kim S, Yigitbasi O G, Mandal M, Jasser S A, Dakak Yazici Y, Schiff B A, El-Naggar A, Bekele B N, Mills G B, Myers J N. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Molecular Cancer Therapeutics 2005; 4: 1146–1156
   PubMed Web of Science ®Google Scholar